CMT Research Foundation
  • What is CMT?
    • Types of CMT
      • What is CMT1?
      • What is CMT2?
      • What is CMT4?
      • What is CMTX?
        • Understanding CMT1X/CMTX1 and GJB1
    • Videos
      • What is CMT?
      • Everything You Need to Know in Five Minutes
      • Demystifying the Drug Development Process
      • How Patients Can Change the Pace of Drug Development
      • How We Get from Today to FDA-Approved Treatments
      • Conversations with Researchers Working in CMT
  • About Us
    • Founders
    • Board of Directors
    • Scientific Advisory Board
    • CMT Research Foundation Staff
    • CMT Research Foundation Advisors
    • Contact Us
    • Financials
  • Research
    • Overview
    • Research Pipeline
    • Research News
    • Research We Fund
    • Clinical Trials
    • CMTRF Research Priorities
    • Apply for CMT Research Foundation Funding
  • News & Events
    • News & Opinion
    • 2022 Global CMT Research Convention
    • 2021 Global CMT Research Convention
  • Take Action
    • Young Professionals Board
    • Ambassadors
    • CMT Clinical Trial Studies
    • CMT1A Endgame
    • Donate
    • Social Media
  • Global CMT Research Convention
  • Donate
Select Page

Give now to accelerate treatments and cures for all types of CMT.

Donate today!

Optimal Dosing Identified in CMT1X Research Update

Jan 31, 2023 | CMT Research Updates, CMTRF Funded Research, Research news

By: Kelsie Timbie A CMT Research Foundation-funded project at the University of Illinois Chicago has identified optimal dosing for a potential therapeutic for CMT1X. Like other forms of CMT, cell-to-cell communication within the peripheral nervous system malfunctions...

CMT2E Gene Therapy Project Successfully Completes Milestone 2

Jan 17, 2023 | CMT Research Updates, CMTRF Funded Research, Gene Therapy, Research news

By: Kelsie Timbie, CMT Research Foundation A collaboration between Dr. Chris Lorson and Dr. Michael Garcia of the University of Missouri and funded by the CMT Research Foundation is producing promising results in an innovative new approach to treating CMT2E. CMT2E...

Italian Research Group Completes CMT Research Foundation-Funded Project, Results Encourage Further Work in New Therapy for Adult and Elderly Patients with CMT1A/CMT1B

Jan 10, 2023 | CMT Research Updates, CMTRF Funded Research, Research news

By: Kelsie Timbie, CMT Research Foundation The CMT Research Foundation is pleased to announce that Dr. Maurizio D’Antonio’s research team at San Raffaele Scientific Institute in Milan, Italy has completed their CMT Research Foundation-funded project...

CMT Research Foundation partners with Samsara Therapeutics to develop a novel class of drugs in CMT1A

Oct 13, 2022 | About CMT, CMT Research Updates, CMTRF Funded Research, Research news

By: Keith Fargo, PhD, Chief Science Officer The CMT Research Foundation is pleased to announce a new project with Samsara Therapeutics, a US/UK-based biotech company that is developing a novel class of drugs for CMT1A. CMT1A is caused by duplication of a stretch of...

CMT Research Foundation and Samsara Therapeutics Partner on a Novel Therapeutic Approach for CMT1A with the Potential to Reach Clinical Trials

Oct 12, 2022 | CMTRF Funded Research, Press Releases, Research news

ATLANTA (October 13, 2022) The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease*, has invested in Samsara Therapeutics Inc., a biotech company focusing on discovering and developing...

CMT Research Foundation Awards $152,524 to ORYZON to test novel HDAC6 inhibitors in CMT1A

Jul 26, 2022 | CMTRF Funded Research, Research news

By: Keith Fargo, PhD, Chief Science Officer New project will examine impact of two selective and potent drug candidates recently discovered by ORYZON The CMT Research Foundation is delighted to announce a new project with ORYZON, a clinical stage pharmaceutical...
« Older Entries

Search Articles

Categories

  • About CMT
  • CMT Research Updates
  • CMTRF Funded Research
  • Drug Development
  • Gene Therapy
  • Life with CMT
  • News
  • Press Releases
  • Research news
  • Small Molecule Therapies
  • Stories
  • Therapy Types
  • Uncategorized

RSS Important Research News Announcements

  • The phenotypic spectrum of pathogenic ATP1A1 variants expands: the novel p.P600R substitution causes demyelinating Charcot-Marie-Tooth disease February 4, 2023
  • Diverse CMT2 neuropathies are linked to aberrant G3BP interactions in stress granules February 3, 2023
  • Retraction: Charcot-Marie-Tooth Disease as a Risk Factor for Periprosthetic Fractures in Tibiotalocalcaneal Fusion With Intramedullary Nailing January 20, 2023
  • INF2 mutations in patients with a broad phenotypic spectrum of Charcot-Marie-Tooth disease and focal segmental glomerulosclerosis January 13, 2023
  • Exercise induced myelin protein zero improvement in neuropathic pain rats January 11, 2023
  • A meta-analysis on the prevalence of Charcot-Marie-Tooth disease and related inherited peripheral neuropathies January 11, 2023
  • X-linked Charcot-Marie-Tooth disease after SARS-CoV-2 vaccination mimicked stroke-like episodes: A case report January 11, 2023
  • Targeting the PMP22 Protein to Develop Leads Against Charcot-Marie-Tooth Disease December 31, 2022
  • Actin-mediated regulation of organelle dynamics in Charcot-Marie-Tooth disease December 31, 2022
  • Electroceutical approach ameliorates intracellular PMP22 aggregation and promotes pro-myelinating pathways in a CMT1A in vitro model December 30, 2022

This website uses cookies to improve your experience. Full details can be found here. Cookie settingsACCEPT REJECT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
Thanks for Your Interest in CMT Research Foundation!

Sign-up to say up-to-date on research news, as well as drug development and clinical advances.

Sign-Up Now!